LU91452I2 - "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)" - Google Patents

"Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"

Info

Publication number
LU91452I2
LU91452I2 LU91452C LU91452C LU91452I2 LU 91452 I2 LU91452 I2 LU 91452I2 LU 91452 C LU91452 C LU 91452C LU 91452 C LU91452 C LU 91452C LU 91452 I2 LU91452 I2 LU 91452I2
Authority
LU
Luxembourg
Prior art keywords
mycaminer
mycafungin
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
LU91452C
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91452(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9420425A external-priority patent/GB9420425D0/en
Priority claimed from GBGB9508745.8A external-priority patent/GB9508745D0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of LU91452I2 publication Critical patent/LU91452I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU91452C 1994-10-07 2008-06-04 "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)" LU91452I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420425A GB9420425D0 (en) 1994-10-07 1994-10-07 New compound
GBGB9508745.8A GB9508745D0 (en) 1995-04-28 1995-04-28 New compound
PCT/JP1995/001983 WO1996011210A1 (fr) 1994-10-07 1995-09-29 Hexapeptides cycliques a activite antibiotique

Publications (1)

Publication Number Publication Date
LU91452I2 true LU91452I2 (fr) 2008-08-04

Family

ID=26305774

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91452C LU91452I2 (fr) 1994-10-07 2008-06-04 "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"

Country Status (27)

Country Link
US (2) US6107458A (fr)
EP (1) EP0788511B1 (fr)
JP (2) JP2897427B2 (fr)
KR (1) KR100353303B1 (fr)
CN (1) CN1203089C (fr)
AR (1) AR041770A1 (fr)
AT (1) ATE229541T1 (fr)
AU (1) AU696949B2 (fr)
BR (2) BRPI9504791B8 (fr)
CA (1) CA2202058C (fr)
DE (2) DE69529172T2 (fr)
DK (1) DK0788511T3 (fr)
ES (1) ES2187575T3 (fr)
FI (1) FI119988B (fr)
FR (1) FR08C0028I2 (fr)
HK (1) HK1004136A1 (fr)
HU (1) HU228151B1 (fr)
IL (1) IL115484A (fr)
LU (1) LU91452I2 (fr)
MX (1) MX9702531A (fr)
NL (1) NL300352I2 (fr)
NO (2) NO328483B1 (fr)
OA (1) OA10475A (fr)
PT (1) PT788511E (fr)
RU (1) RU2165423C2 (fr)
TR (1) TR199501229A2 (fr)
WO (1) WO1996011210A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
US6291680B1 (en) * 1997-06-18 2001-09-18 Fujisawa Pharmaceutical Co., Ltd. Production process
AU756792B2 (en) * 1998-02-09 2003-01-23 Fujisawa Pharmaceutical Co., Ltd. New compound
EP1053247A1 (fr) * 1998-02-09 2000-11-22 Fujisawa Pharmaceutical Co., Ltd. Nouveau compose
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
ATE311373T1 (de) * 1999-02-11 2005-12-15 Emisphere Tech Inc Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
AUPP999799A0 (en) 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
US7166572B1 (en) 1999-07-27 2007-01-23 Aventis Pharma Deutschland Gmbh Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
TWI250992B (en) 2000-02-21 2006-03-11 Astellas Pharma Inc Polypeptide compounds for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms
ES2191516B1 (es) * 2000-07-28 2005-01-01 Consejo Superior De Investigaciones Cientificas Antibioticos antifungicos de naturaleza peptidica inhibidores de la germinacion y el crecimiento de hongos fitopatogenos.
AUPQ938700A0 (en) * 2000-08-14 2000-09-07 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
JP2005053782A (ja) * 2001-08-31 2005-03-03 Fujisawa Pharmaceut Co Ltd 環状リポペプチド化合物の新規結晶
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
WO2004014879A1 (fr) * 2002-08-08 2004-02-19 Fujisawa Pharmaceutical Co., Ltd. Procede de preparation d'acides isoxazolyle-benzoiques
AU2003903205A0 (en) * 2003-06-23 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. New compound
ATE381957T1 (de) * 2003-07-22 2008-01-15 Theravance Inc Verwendung eines antimykotischen echinocandin- mittels in kombination mit einem antibakteriellen glycopeptid-mittel
CA2537574A1 (fr) * 2003-09-05 2005-03-24 Merck & Co., Inc. Phases stationnaires et procede de purification mettant en oeuvre lesdites phases
US7547693B2 (en) * 2003-09-22 2009-06-16 Banyu Pharmaceutical Co. Ltd. Piperidine derivative
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
EP1768968A1 (fr) * 2004-05-20 2007-04-04 Foldrx Pharmaceuticals, Inc. Composes 2-(heteroaryl)benzoxazoles et derives, compositions et procedes servant a stabiliser la transthyretine et a inhiber le mauvais repliement de la transthyretine
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1804799B1 (fr) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'agents thérapeutiques
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
AU2005286731A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
CA2580856A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP1815206B1 (fr) * 2004-10-13 2016-04-06 PTC Therapeutics, Inc. Composes de suppression de non-sens et procedes de leur utilisation
EP2029138A1 (fr) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
US7947707B2 (en) * 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
CA2699980C (fr) 2007-08-13 2015-06-02 Divergence, Inc. Compositions et procedes pour lutter contre les nematodes
CN101861330A (zh) * 2007-10-29 2010-10-13 安斯泰来制药有限公司 多肽化合物
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
AU2009271328B2 (en) * 2008-06-24 2012-09-06 Irm Llc Compounds and methods for modulating G protein-coupled receptors
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
BR112013023531A2 (pt) * 2011-04-04 2016-12-06 Xellia Pharmaceuticals Aps processo de um único vaso para a fabricação de micafungina ou de um sal desta
SI2699327T1 (sl) 2011-04-20 2015-11-30 Xelia Pharmaceuticals Aps Postopek čiščenja mikafungina
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
EP2709609B1 (fr) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Composés hétérocycliques
HUE029720T2 (en) 2011-09-09 2017-03-28 Sandoz Ag Preparation of micafungin intermediates
CN102659930B (zh) * 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
CN102627689B (zh) * 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
CN102627688B (zh) 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
JP6491325B2 (ja) * 2014-05-29 2019-03-27 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｔｅｃｈｗｅｌｌ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ シクロペプチド系化合物の溶媒和物およびその製造方法と使用
WO2016056023A2 (fr) * 2014-10-07 2016-04-14 Alaparthi Lakshmi Prasad Produits intermédiaires et procédés de préparation de micafungine
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
EP3485873A1 (fr) 2017-11-17 2019-05-22 Cadila Healthcare Limited Compositions injectables pharmaceutiques stables de micafungine
CN108752430B (zh) * 2018-05-31 2022-02-18 杭州中美华东制药有限公司 米卡芬净钠新晶型及其制备方法
WO2020013116A1 (fr) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Inhibiteur de ptp-1b et son utilisation
CN110734408A (zh) * 2019-10-22 2020-01-31 重庆康乐制药有限公司 一种米卡芬净类衍生物侧链中间体的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE990233A1 (en) * 1990-06-18 2000-11-15 Fujisawa Pharmaceutical Co New Polypeptide Compound and a Process for Preparation thereof
TW264477B (fr) * 1992-03-19 1995-12-01 Lilly Co Eli

Also Published As

Publication number Publication date
BRPI9504791B8 (pt) 2019-12-31
NO971544D0 (no) 1997-04-04
JP3518665B2 (ja) 2004-04-12
CA2202058C (fr) 2007-11-06
FI971397A0 (fi) 1997-04-04
FR08C0028I1 (fr) 2008-08-15
US6265536B1 (en) 2001-07-24
NO328483B1 (no) 2010-03-01
NL300352I1 (nl) 2008-08-01
IL115484A0 (en) 1996-01-19
DK0788511T3 (da) 2003-03-31
AU696949B2 (en) 1998-09-24
HU228151B1 (en) 2012-12-28
AU3578095A (en) 1996-05-02
CA2202058A1 (fr) 1996-04-18
HK1004136A1 (en) 1998-11-20
PT788511E (pt) 2003-04-30
WO1996011210A1 (fr) 1996-04-18
KR970707150A (ko) 1997-12-01
DE69529172T2 (de) 2003-04-17
FR08C0028I2 (fr) 2009-11-20
TR199501229A2 (tr) 1996-07-21
RU2165423C2 (ru) 2001-04-20
ATE229541T1 (de) 2002-12-15
NL300352I2 (nl) 2008-11-03
BR9504791A (pt) 1996-10-22
OA10475A (en) 2002-04-08
JP2897427B2 (ja) 1999-05-31
CN1203089C (zh) 2005-05-25
EP0788511B1 (fr) 2002-12-11
EP0788511A1 (fr) 1997-08-13
FI119988B (fi) 2009-05-29
MX9702531A (es) 1997-06-28
BR9504791B1 (pt) 2010-10-05
NO971544L (no) 1997-06-04
ES2187575T3 (es) 2003-06-16
CN1168675A (zh) 1997-12-24
DE122008000025I2 (de) 2011-02-17
DE69529172D1 (de) 2003-01-23
AR041770A1 (es) 2005-06-01
US6107458A (en) 2000-08-22
FI971397A (fi) 1997-05-27
JPH10324695A (ja) 1998-12-08
NO2010016I2 (no) 2011-10-17
IL115484A (en) 2000-07-16
JPH10507174A (ja) 1998-07-14
DE122008000025I1 (de) 2008-08-21
HUT77736A (hu) 1998-07-28
KR100353303B1 (ko) 2003-01-15
NO2010016I1 (no) 2010-08-16

Similar Documents

Publication Publication Date Title
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU91291I2 (fr) Deferasirox et ses sels pharmaceutiquement acceptables (EXJADEr)
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU91147I2 (fr) Pemetrexed et ses sels pharmaceutiquement acceptables.
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU91345I2 (fr) Rufinamide et ses sels pharmaceutiquement acceptables (inovelon)
LU91437I2 (fr) "dabigatran-etexilate et ses sels- particulièrement dabigatran-etexilate-mésilate (PRADAXA)"
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
MC2263A1 (fr) Aminobenzodiazepines et leurs sels pharmaceutiquement acceptables
LU90844I2 (fr) es Riamet et ses d-riv-s pharmaceutiquement acceptabl
LU92564I2 (fr) Médocaril de ceftobiprole et les sels pharmaceutiquement acceptables qui en dérivent
DK0821692T3 (da) Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf
ITGE940099A0 (it) Dispositivo per l'agugliatura di una falda di ovatta.
ITMI962503A0 (it) Procedimento per progettare una apparecchiatura impiegante superconduttivita' e apparecchiatura impiegante superconduttivita'
KR940005143U (ko) 유희용 라켓
LU90110I2 (fr) Penciclovir et ses dérivés pharmaceutiquement acceptables
ITGE940106A0 (it) Dispositivo per l'agugliatura di una falda di ovatta.
KR940001899U (ko) 네온 변압기의 접속구
KR960038365U (ko) 피엘씨의 입출력 증설장치
ZA937286B (en) Immunopotentiatory agents and physiologically acceptable salts thereof
GB9226874D0 (en) Immunopotentiatory agents and physiologically acceptable salts thereof